Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms

Journal of Virology

Volumn 87, Issue 14, 2013, Pages 8017-8028

  Adedeji, Adeyemi O ^a   Severson, William ^b   Jonsson, Colleen ^c   Singh, Kamalendra ^a   Weiss, Susan R ^d   Sarafianosa, Stefan G ^a  

^a University of Missouri   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF LOUISVILLE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(1 THIOPHEN 2 YLETHYLIDENEAMINO)THIOUREA; ANGIOTENSIN CONVERTING ENZYME 2; ANTIVIRUS AGENT; CATHEPSIN L; N (9,10 DIOXO 9,10 DIHYDROANTHRACEN 2 YL)BENZAMIDE; N [[4 (4 METHYLPIPERAZIN 1 YL)PHENYL]METHYL] 1,2 OXAZOLE 5 CARBOXAMIDE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME SPECIFICITY; HOST CELL; MOLECULAR INTERACTION; MOLECULAR LIBRARY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARS CORONAVIRUS; VIRION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS INHIBITION; VIRUS REPLICATION;

ANTHRACENES; BENZAMIDES; BLOTTING, WESTERN; CATHEPSIN B; CATHEPSIN L; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUOROMETRY; HEK293 CELLS; HUMANS; IMMUNOPRECIPITATION; LUCIFERASES; OXAZOLES; PEPTIDYL-DIPEPTIDASE A; PIPERAZINES; REAL-TIME POLYMERASE CHAIN REACTION; SARS VIRUS; SMALL MOLECULE LIBRARIES; THIOPHENES; THIOUREA; VIRUS INTERNALIZATION;

EID: 84880320822     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00998-13     Document Type: Article

References (76)

1. Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, Chu CM, Hui PK, Mak KL, Lim W, Yan KW, Chan KH, Tsang NC, Guan Y, Yuen KY, Peiris JS. 2003. Lung pathology of fatal severe acute respiratory syndrome. Lancet 361:1773-1778.
2. Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, Green K, Tellier R, Draker R, Adachi D, Ayers M, Chan AK, Skowronski DM, Salit I, Simor AE, Slutsky AS, Doyle PW, Krajden M, Petric M, Brunham RC, McGeer AJ. 2003. Identification of severe acute respiratory syndrome in Canada. N. Engl. J. Med. 348:1995-2005.
3. Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, Walmsley SL, Mazzulli T, Avendano M, Derkach P, Ephtimios IE, Kitai I, Mederski BD, Shadowitz SB, Gold WL, Hawryluck LA, Rea E, Chenkin JS, Cescon DW, Poutanen SM, Detsky AS. 2003. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 289:2801-2809.
4. Frieman M, Basu D, Matthews K, Taylor J, Jones G, Pickles R, Baric R, Engel DA. 2011. Yeast based small molecule screen for inhibitors of SARSCoV. PLoS One 6:e28479. doi:10.1371/journal.pone.0028479.
5. Hsu LY, Lee CC, Green JA, Ang B, Paton NI, Lee L, Villacian JS, Lim PL, Earnest A, Leo YS. 2003. Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts. Emerg. Infect. Dis. 9:713-717.
6. Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, Dijkman R, Muth D, Demmers JA, Zaki A, Fouchier RA, Thiel V, Drosten C, Rottier PJ, Osterhaus AD, Bosch BJ, Haagmans BL. 2013. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495:251-254.
7. Bupp K, Roth MJ. 2005. Alteration and analyses of viral entry with library-derived peptides. Adv. Virus Res. 65:147-172.
8. Douglas JL, Panis ML, Ho E, Lin KY, Krawczyk SH, Grant DM, Cai R, Swaminathan S, Cihlar T. 2003. Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. J. Virol. 77:5054-5064.
9. Razinkov V, Gazumyan A, Nikitenko A, Ellestad G, Krishnamurthy G. 2001. RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein. Chem. Biol. 8:645-659.
10. Lieberman-Blum SS, Fung HB, Bandres JC. 2008. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. Clin. Ther. 30: 1228-1250.
11. MacArthur RD, Novak RM. 2008. Reviews of anti-infective agents. Maraviroc: the first of a new class of antiretroviral agents. Clin. Infect. Dis. 47:236-241.
12. Wood A, Armour D. 2005. The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. Prog. Med. Chem. 43:239-271.
13. Anonymous. 1999. Pentafuside. DP 178, T 20. Drugs R D 2:347-349.
14. Berkhout B, Eggink D, Sanders RW. 2012. Is there a future for antiviral fusion inhibitors? Curr. Opin. Virol. 2:50-59.
15. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, Kappes JC, Shaw GM, Hunter E. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74:8358-8367.
16. Hartt JK, Liang T, Sahagun-Ruiz A, Wang JM, Gao JL, Murphy PM. 2000. The HIV-1 cell entry inhibitor T-20 potently chemoattracts neutrophils by specifically activating the N-formylpeptide receptor. Biochem. Biophys. Res. Commun. 272:699-704.
17. Miller MD, Hazuda DJ. 2004. HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications. Drug Resist. Updat. 7:89-95.
18. Naito T, Izumi K, Kodama E, Sakagami Y, Kajiwara K, Nishikawa H, Watanabe K, Sarafianos SG, Oishi S, Fujii N, Matsuoka M. 2009. SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide. Antimicrob. Agents Chemother. 53:1013-1018.
19. Eda Y, Murakami T, Ami Y, Nakasone T, Takizawa M, Someya K, Kaizu M, Izumi Y, Yoshino N, Matsushita S, Higuchi H, Matsui H, Shinohara K, Takeuchi H, Koyanagi Y, Yamamoto N, Honda M. 2006. Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection. J. Virol. 80:5563-5570.
20. Matsushita S, Takahama S, Shibata J, Kimura T, Shiozaki K, Eda Y, Koito A, Murakami T, Yoshimura K. 2005. Ex vivo neutralization of HIV-1 quasi-species by a broadly reactive humanized monoclonal antibody KD-247. Hum. Antibodies 14:81-88.
21. Cilliers T, Willey S, Sullivan WM, Patience T, Pugach P, Coetzer M, Papathanasopoulos M, Moore JP, Trkola A, Clapham P, Morris L. 2005. Use of alternate coreceptors on primary cells by two HIV-1 isolates. Virology 339:136-144.
22. Dau B, Holodniy M. 2009. Novel targets for antiretroviral therapy: clinical progress to date. Drugs 69:31-50. 23. Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. 2003. Coronavirus main proteinase (3CLpro) structure: basis for design of anti- SARS drugs. Science 300:1763-1767.
23. Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. 2003. Coronavirus main proteinase (3CLpro) structure: basis for design of anti- SARS drugs. Science 300:1763-1767.
24. Perlman S, Netland J. 2009. Coronaviruses post-SARS: update on replication and pathogenesis. Nat. Rev. Microbiol. 7:439-450. 25. Bosch BJ, van der Zee R, de Haan CA, Rottier PJ. 2003. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J. Virol. 77:8801-8811.
25. Bosch BJ, van der Zee R, de Haan CA, Rottier PJ. 2003. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J. Virol. 77:8801-8811.
26. Hofmann H, Geier M, Marzi A, Krumbiegel M, Peipp M, Fey GH, Gramberg T, Pohlmann S. 2004. Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. Biochem. Biophys. Res. Commun. 319:1216-1221.
27. Simmons G, Gosalia DN, Rennekamp AJ, Reeves JD, Diamond SL, Bates P. 2005. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl. Acad. Sci. U. S. A. 102:11876-11881.
28. Tripet B, Howard MW, Jobling M, Holmes RK, Holmes KV, Hodges RS. 2004. Structural characterization of the SARS-coronavirus spike S fusion protein core. J. Biol. Chem. 279:20836-20849.
29. Wong SK, Li W, Moore MJ, Choe H, Farzan M. 2004. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensinconverting enzyme 2. J. Biol. Chem. 279:3197-3201.
30. Yang ZY, Huang Y, Ganesh L, Leung K, Kong WP, Schwartz O, Subbarao K, Nabel GJ. 2004. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J. Virol. 78:5642-5650.
31. Dimitrov DS. 2003. The secret life of ACE2 as a receptor for the SARS virus. Cell 115:652-653.
32. Xiao X, Chakraborti S, Dimitrov AS, Gramatikoff K, Dimitrov DS. 2003. The SARS-CoV S glycoprotein: expression and functional characterization. Biochem. Biophys. Res. Commun. 312:1159-1164.
33. DeDiego ML, Nieto-Torres JL, Jimenez-Guardeno JM, Regla-Nava JA, Alvarez E, Oliveros JC, Zhao J, Fett C, Perlman S, Enjuanes L. 2011. Severe acute respiratory syndrome coronavirus envelope protein regulates cell stress response and apoptosis. PLoS Pathog. 7:e1002315. doi:10.1371/journal.ppat.1002315.
34. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. 2003. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 361:2045-2046.
35. Haga S, Nagata N, Okamura T, Yamamoto N, Sata T, Sasazuki T, Ishizaka Y. 2010. TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds. Antiviral Res. 85:551-555.
36. Knowles SR, Phillips EJ, Dresser L, Matukas L. 2003. Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. Clin. Infect. Dis. 37:1139-1142.
37. Shah PP, Wang T, Kaletsky RL, Myers MC, Purvis JE, Jing H, Huryn DM, Greenbaum DC, Smith AB, 3rd, Bates P, Diamond SL. 2010. A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and Ebola pseudotype virus infection into human embryonic kidney 293T cells. Mol. Pharmacol. 78:319-324.
38. Struck AW, Axmann M, Pfefferle S, Drosten C, Meyer B. 2012. A hexapeptide of the receptor-binding domain of SARS corona virus spike protein blocks viral entry into host cells via the human receptor ACE2. Antiviral Res. 94:288-296.
39. van Vonderen MG, Bos JC, Prins JM, Wertheim-van Dillen P, Speelman P. 2003. Ribavirin in the treatment of severe acute respiratory syndrome (SARS). Neth. J. Med. 61:238-241.
40. Zhou Y, Agudelo J, Lu K, Goetz DH, Hansell E, Chen YT, Roush WR, McKerrow J, Craik CS, Amberg SM, Simmons G. 2011. Inhibitors of SARS-CoV entry-identification using an internally-controlled dual envelope pseudovirion assay. Antiviral Res. 92:187-194.
41. Adedeji AO, Singh K, Calcaterra NE, Dediego ML, Enjuanes L, Weiss S, Sarafianos SG. 2012. Severe acute respiratory virus syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase. Antimicrob. Agents Chemother. 56:4718-4728.
42. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:3-26.
43. Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, Bates P. 2004. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc. Natl. Acad. Sci. U. S. A. 101:4240-4245.
44. Farzan M, Mirzabekov T, Kolchinsky P, Wyatt R, Cayabyab M, Gerard NP, Gerard C, Sodroski J, Choe H. 1999. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 96:667-676.
45. Mangor JT, Monsma SA, Johnson MC, Blissard GW. 2001. A GP64-null baculovirus pseudotyped with vesicular stomatitis virus G protein. J. Virol. 75:2544-2556.
46. Frankel AD, Pabo CO. 1988. Cellular uptake of the Tat protein from human immunodeficiency virus. Cell 55:1189-1193.
47. Platt EJ, Bilska M, Kozak SL, Kabat D, Montefiori DC. 2009. Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J. Virol. 83:8289-8292.
48. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72: 2855-2864.
49. Takeuchi Y, McClure MO, Pizzato M. 2008. Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J. Virol. 82:12585-12588.
50. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
51. Wang H, Blair CD, Olson KE, Clem RJ. 2008. Effects of inducing or inhibiting apoptosis on Sindbis virus replication in mosquito cells. J. Gen. Virol. 89:2651-2661.
52. Severson WE, Shindo N, Sosa M, Fletcher T, 3rd, White EL, Ananthan S, Jonsson CB. 2007. Development and validation of a high-throughput screen for inhibitors of SARS CoV and its application in screening of a 100,000-compound library. J. Biomol. Screen. 12:33-40.
53. Zhang JH, Chung TD, Oldenburg KR. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4:67-73.
54. Durk RC, Singh K, Cornelison CA, Rai DK, Matzek KB, Leslie MD, Schafer E, Marchand B, Adedeji A, Michailidis E, Dorst CA, Moran J, Pautler C, Rodriguez LL, McIntosh MA, Rieder E, Sarafianos SG. 2010. Inhibitors of foot and mouth disease virus targeting a novel pocket of the RNA-dependent RNA polymerase. PLoS One 5:e15049. doi:10.1371/journal.pone.0015049.
55. Almazan F, Dediego ML, Galan C, Escors D, Alvarez E, Ortego J, Sola I, Zuniga S, Alonso S, Moreno JL, Nogales A, Capiscol C, Enjuanes L. 2006. Construction of a severe acute respiratory syndrome coronavirus infectiouscDNAclone and a replicon to study coronavirusRNAsynthesis. J. Virol. 80:10900-10906.
56. Regan AD, Shraybman R, Cohen RD, Whittaker GR. 2008. Differential role for low pH and cathepsin-mediated cleavage of the viral spike protein during entry of serotype II feline coronaviruses. Vet. Microbiol. 132:235-248.
57. Glowacka I, Bertram S, Muller MA, Allen P, Soilleux E, Pfefferle S, Steffen I, Tsegaye TS, He Y, Gnirss K, Niemeyer D, Schneider H, Drosten C, Pohlmann S. 2011. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J. Virol. 85:4122-4134.
58. Huang IC, Bosch BJ, Li F, Li W, Lee KH, Ghiran S, Vasilieva N, Dermody TS, Harrison SC, Dormitzer PR, Farzan M, Rottier PJ, Choe H. 2006. SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. J. Biol. Chem. 281:3198-3203.
59. Skehel JJ, Wiley DC. 2000. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69:531-569.
60. Simmons G, Bertram S, Glowacka I, Steffen I, Chaipan C, Agudelo J, Lu K, Rennekamp AJ, Hofmann H, Bates P, Pohlmann S. 2011. Different host cell proteases activate the SARS-coronavirus spike-protein for cellcell and virus-cell fusion. Virology 413:265-274.
61. Glowacka I, Bertram S, Herzog P, Pfefferle S, Steffen I, Muench MO, Simmons G, Hofmann H, Kuri T, Weber F, Eichler J, Drosten C, Pohlmann S. 2010. Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63. J. Virol. 84:1198-1205.
62. Chen CL, Venkatachalam TK, Waurzyniak B, Chelstrom L, Uckun FM. 2001. In vivo toxicity, pharmacokinetic features and tissue distribution of N-[2-(2,5-dimethoxyphenylethyl)]-N=-[2-(5-bromopyridyl)]-thiourea (HI-236), a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase. Arzneimittelforschung 51:574-581.
63. Kang IJ, Wang LW, Yeh TK, Lee CC, Lee YC, Hsu SJ, Wu YS, Wang JC, Chao YS, Yueh A, Chern JH. 2010. Synthesis, activity, and pharmacokinetic properties of a series of conformationally-restricted thiourea analogs as novel hepatitis C virus inhibitors. Bioorg. Med. Chem. 18:6414-6421.
64. Jardetzky TS, Lamb RA. 2004. Virology: a class act. Nature 427:307-308.
65. Gentile G, Merlo G, Pozzan A, Bernasconi G, Bax B, Bamborough P, Bridges A, Carter P, Neu M, Yao G, Brough C, Cutler G, Coffin A, Belyanskaya S. 2012. 5-Aryl-4-carboxamide-1,3-oxazoles: potent and selective GSK-3 inhibitors. Bioorg. Med. Chem. Lett. 22:1989-1994.
66. Qian Y, Wertheimer SJ, Ahmad M, Cheung AW, Firooznia F, Hamilton MM, Hayden S, Li S, Marcopulos N, McDermott L, Tan J, Yun W, Guo L, Pamidimukkala A, Chen Y, Huang KS, Ramsey GB, Whittard T, Conde-Knape K, Taub R, Rondinone CM, Tilley J, Bolin D. 2011. Discovery of orally active carboxylic acid derivatives of 2-phenyl-5-trifluoromethyloxazole-4-carboxamide as potent diacylglycerol acyltransferase- 1 inhibitors for the potential treatment of obesity and diabetes. J. Med. Chem. 54:2433-2446.
67. Kim YW, Kim YK, Lee JY, Chang KT, Lee HJ, Kim DK, Sheen YY. 2008. Pharmacokinetics and tissue distribution of 3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methyl)benzamide; a novel ALK5 inhibitor and a potential anti-fibrosis drug. Xenobiotica 38:325-339.
68. Huang IC, Bailey CC, Weyer JL, Radoshitzky SR, Becker MM, Chiang JJ, Brass AL, Ahmed AA, Chi X, Dong L, Longobardi LE, Boltz D, Kuhn JH, Elledge SJ, Bavari S, Denison MR, Choe H, Farzan M. 2011. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog. 7:e1001258. doi:10.1371/journal.ppat.1001258.
69. Shulla A, Heald-Sargent T, Subramanya G, Zhao J, Perlman S, Gallagher T. 2011. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J. Virol. 85:873-882.
70. Yang N, Ma P, Lang J, Zhang Y, Deng J, Ju X, Zhang G, Jiang C. 2012. Phosphatidylinositol 4-kinase IIIbeta is required for severe acute respiratory syndrome coronavirus spike-mediated cell entry. J. Biol. Chem. 287: 8457-8467.
71. Li F, Li W, Farzan M, Harrison SC. 2005. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309: 1864-1868.
72. Li W, Zhang C, Sui J, Kuhn JH, Moore MJ, Luo S, Wong SK, Huang IC, Xu K, Vasilieva N, Murakami A, He Y, Marasco WA, Guan Y, Choe H, Farzan M. 2005. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 24:1634-1643.
73. Lankelma JM, Voorend DM, Barwari T, Koetsveld J, Van der Spek AH, De Porto AP, Van Rooijen G, Van Noorden CJ. 2010. Cathepsin L, target in cancer treatment? Life Sci. 86:225-233.
74. Leto G, Sepporta MV, Crescimanno M, Flandina C, Tumminello FM. 2010. Cathepsin L in metastatic bone disease: therapeutic implications. Biol. Chem. 391:655-664.
75. Xu X, Yuan G, Liu W, Zhang Y, Chen W. 2009. Expression of cathepsin L in nasopharyngeal carcinoma and its clinical significance. Exp. Oncol. 31:102-105.
76. Gierer S, Bertram S, Kaup F, Wrensch F, Heurich A, Kramer-Kuhl A, Welsch K, Winkler M, Meyer B, Drosten C, Dittmer U, von Hahn T, Simmons G, Hofmann H, Pohlmann S. 2013. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J. Virol. 87:5502-5511.